Abstract library

19 results for "Feelders".
#186 Occurrence of Other Primary Malignancies in Patients with Endocrine Tumors of the Digestive Tract and Pancreas
Introduction: Endocrine tumors of the digestive tract and pancreas (GEP-NET) are often considered to be associated with other primary malignancies.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Kimberly Kamp
#269 Expression of IGF/mTOR Pathway Components in Human Pheochromocytomas and In Vitro Inhibition of PC12 Rat Pheochromocytoma Cell Growth by mTOR Inhibitors
Introduction: The pathogenesis of pheochromocytomas (pheo) is poorly understood and malignant pheo need new treatment options. mTOR inhibitors, as sirolimus(S) and everolimus(E), are promising antineoplastic drugs.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: MD Maria Cristina De Martino
#467 Thoracic and Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) and Ectopic Adrenocorticotropin (ACTH) Syndrome (EAS)
Introduction: Ectopic Adrenocorticotropin (ACTH) Syndrome (EAS) is associated with a variety of malignancies, mostly of neuroendocrine origin. Several series report on the relative contribution of EAS in the spectrum of Cushing’s syndrome. However, information on the incidence/prevalence of EAS in the setting of patients diagnosed with thoracic or gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) is virtually absent.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Drs. Kimberly Kamp
Keywords: ACTH, GEP-NETS, Cushing
#665 Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate
Introduction: Surgery is the only potential for cure in patients with pancreatic neuroendocrine tumors (pNETs).
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Esther I Van Vliet
#670 The Relationship Between the Ki-67 Protein and IGF-Related Genes in Gastroenteropancreatic Neuroendocrine Tumor Patients with Normal and Elevated Serum Chromogranin-A
Introduction: GEP-NETs are rare, heterogeneous neoplasms with a distinct biological and clinical behavior. Both IGF-system and Ki-67 indices have been reported as important stimulating factors in carcinogenesis and/or tumor progression. The tumor marker CgA is an independent predictor for survival as well. Currently no data are available about a possible interaction between IGF-system (IGF(-R)s, IRs, BPs) and Ki-67 protein in GEP-NET patients with normal and elevated serum CgA.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Drs Roxanne Van Adrichem
Keywords: GEP-NET
#712 A Retrospective Analysis of Safety and Efficacy of Everolimus in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients That Showed Progression after PRRT
Introduction: GEP-NET patients have been treated successfully with SSAs. Upon progression, peptide receptor radiotherapy (PRRT) with 177Lu-octreotate is successful. PRRT is not unlimited. Some patients became refractory after therapy. There is a high medical need. Everolimus (mTOR inhibitor) is a promising therapy for progressive G1/G2 GEP-NETs, with well-established safety. Everolimus has shown efficacy in patients with (non-)PNET (RADIANT-2/-3). However, toxicity data of Everolimus after PRRT is lacking.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: drs. Kimberly Kamp
Authors: Kamp K, Feelders R, De Herder W, ...
#850 Expression of IGF/mTOR Pathway Components in Human Pheochromocytomas and In Vitro Inhibition of PC12 rat Pheochromocytoma Cell Growth by mTOR Inhibitors alone and in Combination with the Dual IGFI-R/INS-R Antagonist OSI-906
Introduction: Dysregulation of the mTOR and IGF pathways have been suggested to be involved in the pathogenesis of pheochromocytomas (PCC). mTOR inhibitors, such as sirolimus (S) and everolimus (E), as well as IGFI-R antagonists such as OSI-906, could be new a treatment for malignant PPC.
Conference: 11th Annual ENETS Conference (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Maria Cristina De Martino
#981 Parathyroid Hormone-Related Peptide (PTHrP) Secretion by Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Clinical Features, Diagnosis, Management, and Long-Term Follow-Up
Introduction: There are a few large series of patients with parathyroid hormone (PTH)-related protein (PTHrP) secreting neuroendocrine tumors (NETs) causing severe hypercalcemia.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Drs Kimberly Kamp
Keywords: PTH, PTHrP, net, hypercalcemia
#1118 Is There an Additional Value of Somatostatin Receptor Subtype 2A Immunohistochemistry Over Somatostatin Receptor Scintigraphy in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
Introduction: It is not known whether tumoral somatostatin receptor subtype 2a (sst2a) immunohistochemistry (IHC) has additional value over OctreoScan® uptake in predicting response to PRRT in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Others
Presenting Author: MD Roxanne Van Adrichem
Keywords: sst2a
#1142 GastroEnteroPancreatic and Thoracic Neuroendocrine Tumors and the Ectopic Adrenocorticotropin Syndrome
Introduction: Ectopic Adrenocorticotropin (ACTH) Syndrome (EAS) is associated with a variety of malignancies, predominantly of neuroendocrine origin. Several series report on the relative contribution of EAS in the spectrum of Cushing’s syndrome. However, information on the incidence/prevalence and prognosis of EAS in the setting of patients diagnosed with Thoracic or GEP-NETs is virtually absent.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: drs. Kimberly Kamp